MedTrace Logo

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

NCT01690741 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2018-06-25

No results posted yet for this study

Summary

This study will be the first to test the anti-cancer peptide Nerofe in humans. It will evaluate the safety, pharmacokinetic behavior, and pharmacodynamic and clinical effects of Nerofe given intravenously every other day to patients with advanced malignant disease.

Conditions

Interventions

DRUG

Nerofe

Nerofe administered intravenously 3x/week

Sponsors & Collaborators

  • Immune System Key Ltd

    lead INDUSTRY

Principal Investigators

  • Yoram Devary, PhD · Immune System Key Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2017-12-19
Completion
2017-12-19

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01690741 on ClinicalTrials.gov